Alcohol, Birth Control, and GLP-1 Drugs: What to Know

Does semaglutide make birth control pills less effective?

The Wegovy, Ozempic injection, and Rybelsus/Ozempic tablet labels do not advise switching birth control methods or adding a barrier method [1][2][3]. Their interaction sections cover insulin, insulin secretagogues such as sulfonylureas, and oral medicines in general [1][2][3]. In a drug interaction study with the semaglutide tablet, ethinyl estradiol and levonorgestrel exposure did not change to a clinically significant degree [1].

The labels do note that semaglutide delays gastric emptying and may affect absorption of oral medicines, and they ask for closer monitoring of drugs with a narrow therapeutic index [1][3]. The Wegovy and Ozempic labels add that in clinical pharmacology trials with the semaglutide 1 mg weekly injection, semaglutide did not affect the absorption of orally administered medicines to a clinically relevant degree [1][2].

A 2024 review in the Journal of the American Pharmacists Association collected six trials on incretin drugs and oral hormonal contraceptives. Five studies of GLP-1 receptor agonists found no statistically or clinically significant effect; the one tirzepatide study found a statistically significant reduction in the contraceptive's area under the curve, maximum concentration and time to maximum concentration [8].

Where the four weeks of backup advice actually comes from

The Zepbound and Mounjaro (tirzepatide) labels tell patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase [4][6]. Tirzepatide is a dual GIP and GLP-1 receptor agonist, not a pure GLP-1 agonist [4].

The Foundayo (orforglipron) label gives the same instruction for 30 days after starting and after each dose escalation, and adds that hormonal contraceptives not administered orally should not be affected [5].

The review's authors suggest an explanation: tirzepatide has a greater effect on gastric emptying than typical GLP-1 receptor agonists, with gastric emptying most substantially delayed after the first dose [8].

Can you drink alcohol while taking semaglutide?

The semaglutide labels give no alcohol-specific restriction, and we found no study that tested drinking with semaglutide, so the absence of a restriction does not establish that drinking is safe. What the labels do cover is blood sugar: semaglutide lowers glucose and raises hypoglycemia risk when taken with insulin or an insulin secretagogue such as a sulfonylurea [1]. In a Wegovy trial in adults with type 2 diabetes and BMI 27 or higher, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg versus 2.5% on placebo, and the risk was higher in people taking a sulfonylurea [1].

A 2022 review in the British Journal of Pharmacology describes rodent and non-human primate studies in which GLP-1 receptor agonists reduced intake of alcohol and drugs of abuse, notes that clinical trials had been started, and states that the precise mechanisms are still to be uncovered [7]. No semaglutide product is approved for alcohol use disorder; the labeled uses are type 2 diabetes, weight management, cardiovascular risk reduction and MASH [1][2].

What if you are planning a pregnancy?

The Wegovy label says weight loss offers no benefit in pregnancy and may cause fetal harm. It advises discontinuing Wegovy when pregnancy is recognized (for weight reduction or cardiovascular risk reduction) and stopping at least 2 months before a planned pregnancy, given semaglutide's half-life of about one week [1]. The Ozempic label gives the same 2-month instruction before a planned pregnancy [2].